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Development of cancer has been linked to chronic
inflammation, particularly via interleukin-23 (IL-23)
and IL-17 signaling pathways. However, the cellular
source of IL-17 and underlyingmechanisms bywhich
IL-17-producing cells promote human colorectal
cancer (CRC) remain poorly defined. Here, we
demonstrate that innate gdT (gdT17) cells are the
major cellular source of IL-17 in human CRC. Micro-
bial products elicited by tumorous epithelial barrier
disruption correlated with inflammatory dendritic
cell (inf-DC) accumulation and gdT17 polarization in
human tumors. Activated inf-DCs induced gdT17
cells to secrete IL-8, tumor necrosis factor alpha,
and GM-CSF with a concomitant accumulation of
immunosuppressive PMN-MDSCs in the tumor.
Importantly, gdT17 cell infiltration positively corre-
latedwith tumor stages and other clinicopathological
features. Our study uncovers an inf-DC-gdT17-PMN-
MDSC regulatory axis in human CRC that correlates
MDSC-meditated immunosuppression with tumor-
elicited inflammation. These findings suggest that
gdT17 cells might be key players in human CRC pro-
gression and have the potential for treatment or
prognosis prediction.
INTRODUCTION
Colorectal cancer (CRC) is one of the most common fatal malig-
nancies worldwide. Links between cancer and inflammationwere first made by Rudolf Virchow in the nineteenth century.
Accumulating evidence has demonstrated that chronic inflam-
mation and cancer are closely linked (Balkwill et al., 2005; Balk-
will and Mantovani, 2001; Coussens and Werb, 2002; Karin,
2006). Cancer-related inflammation promotes tumor develop-
ment and progression through many different mechanisms,
such as promoting angiogenesis and metastasis, subverting
immune responses, and altering responses to chemotherapeutic
agents (Mantovani et al., 2008). A persistent inflamed microenvi-
ronment can also trigger mutagenic processes that serve
as cancer-initiating events. Further tumor progression is
augmented by the continuous presence of inflammatory cells
and cytokines, which might transform an inflamedmicroenviron-
ment into an immunosuppressive milieu (Grivennikov et al.,
2010). Accordingly, treatment with nonsteroidal anti-inflamma-
tory agents has shown decreased incidence and mortality in
several tumor types (Rothwell et al., 2010).
The interleukin-23 (IL-23)-IL-17 axis plays a critical role in
human CRC (Grivennikov et al., 2012; Langowski et al., 2006)
and T helper 17 (Th17) cell expression signatures in CRC have
been shown to be associated with poor survival (Grivennikov
et al., 2012; Zou and Restifo, 2010). Although Th17 cells are
implicated to predominately produce IL-17 in murine colon
cancer models (Grivennikov et al., 2012), the source of IL-17 in
human CRC has not been defined. In addition, the underlying
mechanisms by which IL-17 and its related cytokines promote
human CRC development and progression remain incompletely
understood.
gdT cells have been recently demonstrated the major innate
source of IL-17 (gdT17) and are known to play a critical role in
autoimmune and inflammatory diseases (Petermann et al.,
2010; Sutton et al., 2009) such as inflammatory bowel disease
(Park et al., 2010), psoriasis (Cai et al., 2011; Pantelyushin
et al., 2012), dermatitis (Gray et al., 2013), and hepatitis (WangImmunity 40, 785–800, May 15, 2014 ª2014 Elsevier Inc. 785
(legend on next page)
Immunity
Innate gdT17 Cells in Human CRC
786 Immunity 40, 785–800, May 15, 2014 ª2014 Elsevier Inc.
Immunity
Innate gdT17 Cells in Human CRCet al., 2013). Recent studies also showed that gdT17 cells could
facilitate tumor growth via promoting angiogenesis in mice
(Silva-Santos, 2010; Wakita et al., 2010). However, the proper-
ties and roles of gdT17 cells in human cancer-related inflamma-
tion have not been examined. Here, we have demonstrated that
tumor-infiltrating gdT17 cells, but not Th17 cells or Tc17 cells, are
the major IL-17A (hereafter referred to as IL-17)-producing cells
in human CRC. Disruption of epithelial barrier in colon led to
bacterial invasion, which correlated with inflammatory DC (inf-
DC) accumulation and activation to secrete IL-23 thus promoting
gdT17 polarization. Activated gdT17 cells also secreted other
cytokines including IL-8, tumor necrosis factor alpha (TNF-a),
and GM-CSF, which might chemoattract polymorphonuclear
myeloid-derived suppressor cells (PMN-MDSCs) in the tumor
and sustain their immunosuppressive activity. Tumor-infiltrating
gdT17 cells positively correlated with advanced tumor clinico-
pathological features. Thus we reveal an inf-DCs-gdT17-PMN-
MDSCs regulatory axis in human CRC that correlates immune
suppression and tumor progression.
RESULTS
gdT17 Cells Are the Predominant IL-17-Producing Cells
in Human CRC
Inflammatory signature genes have been shown to be upregu-
lated in human CRC (Reichling et al., 2005; Wood et al., 2007).
We found that IL-17 was increased both at the level of transcrip-
tion and protein expression (Figure S1A and S1B) in human CRC
tissues. To investigate the source of IL-17, we prepared single
cell suspensions from tumor and fresh paired normal tissues.
We found that the major IL-17-producing cells were CD3+
T cells (Figure 1A, left) in tumor. The percentages and absolute
numbers of both IL-17+ cells in CD45+ cells and CD3+ cells
were substantially increased in tumor compared with paired
normal tissues (Figure 1A, right). Furthermore, we found that
IL-17 was produced by CD8+ T cells (Tc17), CD4+ T cells
(Th17), and gdTCR+ T cells (gdT17) (Figure 1B, left) but not innate
lymphoid cells (ILCs) (Figure S1C). The percentages and abso-
lute numbers of Tc17, Th17, and gdT17 cells were substantially
increased in tumor tissues compared to those in paired normal
tissues (Figure 1B, right). Among all IL-17-producing cells, the
percentages and absolute numbers of gdT17 cells were muchFigure 1. gdT17 Cells Are the Major Source of IL-17 in Human CRC
Intracellular IL-17 production assessed by flow cytometry (FCM) on single cell su
(A) Left panel shows representative flow cytometric analysis of CD3+ IL-17A+ cells
of 34 independent experiments is shown. Right panel shows bar diagram that su
CD3+ cells (middle), as well as absolute numbers (right) of CD3+ IL-17A+ cells in CD
n = 34; *p < 0.05; **p < 0.01.
(B) Left panel representative flow cytometric analysis of IL-17 secretion from CD
bottom) in tumor and paired normal tissues. Plots were gated on CD45+ CD3+ CD
one of 28 independent experiments is shown. Right panel bar diagram summariz
and gdTCR+ T cells, and absolute numbers (right) of Tc17, Th17, and gdT17 cells
SEM; n = 28; *p < 0.05; **p < 0.01.
(C) Summarized data show the percentages (left) and absolute numbers (right) of
n = 28; **p < 0.01; ***p < 0.001.
(D) Paraffin sections from CRC patients (scale bars represent 100 mM) were s
immunofluorescent (IF) staining. Right panel (scale bars represent 100 mM) is the
the colocalization of gdTCR and IL-17A in tumor. One of three independent expe
See also Figure S1.more than Tc17 cells and Th17 cells in tumor (Figure 1C). ELISA
analysis also revealed that gdT17 cells secreted much more
IL-17 than Th17 or Tc17 cells (Figure S1D). These gdT17 cells
were readily seen in tumor as revealed by immunofluorescent
(IF) staining. IL-17 was colocalized with gdTCR+ cells in the
tumor border (Figure 1D). Furthermore, we found that IL-17
production was greatly elevated in tumor-infiltrating gdT cells
(Figure S1E), whereas interferon-g (IFN-g) production was not
substantially altered (Figure S1F). These results indicate that
gdT17 cells are the major IL-17-producing cells in human CRC.
Characteristics and Distribution of gdT17 Cells in
Human CRC
We next examined the characteristics of gdT17 cells in human
CRC. We found that approximately 80%–90% of gdT cells
isolated from normal and tumor tissues expressed CD69,
whereas fewer than 50% of gdT cells in peripheral blood (PB)
from corresponding patients were CD69+ (Figure S2A). In addi-
tion to IL-17A, a small quantity of gdT17 cells also produced
IL-17F (Figure S2B). It was notable that most gdT17 cells in
normal and tumor tissues also produced TNF-a, but not IFN-g
(Figure 2A). Moreover, gdT17 cells produced more TNF-a in
tumor than that in paired normal tissues (Figure S2C). In contrast,
Th17 cells secreted low amounts of TNF-a (Figure S2D). Further-
more, gdT17 cells from normal and tumor tissues did not pro-
duce appreciable amounts of IL-22, IL-10, or IL-4 (Figure 2B).
Human gdT cells have two major Vd gene usages (Vantourout
and Hayday, 2013). The majority of gdT17 cells (67.4%–83.6%)
in tumor tissues were Vd1+ cells while fewer than 10% of
gdT17 cells expressed Vd2 (Figure 2C). Tumor-infiltrating
gdT17 cells were CD45RO+, CD161+, and CCR6+ cells (Fig-
ure 2D; Figure S2E), but granzyme B, perforin, FasL, TRAIL,
NKG2D, NKp30, NKp44, NKp46, CD25, and CD122 were nega-
tive. Interestingly, most gdT17 cells in normal tissues were of
central memory T cell phenotype (Tcm, CD45RA CD27+),
whereas gdT17 cells in tumor tissues were effector memory
T cells (Tem, CD45RA CD27) (Figure 2E). However, the other
surface markers expression did not reveal any difference on
gdT17 cells from the tumors or paired tissues (Figure S2F). To
further analyze the distribution of gdT17 cells in human CRC,
we prepared single cell suspensions from paired normal, tumor
border, and intratumor tissues. gdT17 cells were substantiallyspensions prepared from tumor and paired normal tissues of CRC patients.
in tumor and paired normal tissues. Plots were gated on CD45+ leukocytes, one
mmarizes the percentages of IL-17A+ cells in the CD45+ cells (left) and CD45+
45+ cells (13 106). N, normal tissue; T, tumor. Data are shown asmean ± SEM;
8+ T cells (Tc17, top), CD4+ T cells (Th17, middle), and gdTCR+ T cells (gdT17,
8+ (top), CD45+ CD3+ CD4+ (middle), or CD45+ CD3+ gdTCR+ T (bottom) cells,
es the percentages (left) of IL-17A+ subpopulations present in the CD8+, CD4+,
in CD45+ cells (13 106). N, normal tissue; T, tumor. Data are shown as mean ±
Tc17, Th17, and gdT17 cells in tumor tissues. Data are shown as mean ± SEM;
tained with anti-human pan-gdTCR (red) and anti-human IL-17A (green) for
magnified view indicated by the red box in the left panel and the arrows display
riments is shown. TB, tumor border; INT, intratumor; N, normal tissue.
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intratumor tissues (approximately 8%–13%) compared with
normal tissues (approximately 1%–6%; Figure 2F). Taken
together, these data suggest that tumor-infiltrating gdT17 cells
are predominantly of the effector memory T cell phenotype and
show unique distribution patterns in human CRC.
Tumor-Infiltrating Inflammatory DCs Trigger gdT17 Cell
Polarization
The IL-23-IL-17 axis has been clearly linked to the tumor-elicited
inflammation in mouse colon cancer models (Grivennikov et al.,
2012). We also found that both transcripts encoding IL-23p19
and IL-23 protein (Figure 3A) were increased in human CRC.
IL-23p19 was expressed by CD11c+ DCs but not CD68+ macro-
phages (Figure 3B) in tumor as revealed by IF staining. To further
determine the cellular source of IL-23 in tumor-infiltrating
myeloid cell subsets, we detected total tumor-infiltrating DCs
(CD45+ Lin HLA-DR+ CD11c+ DCs) and different DC subsets
(Figure S3A) by flow cytometry (FCM). We found that both the
percentages and absolute numbers of total DCs (Figure 3C)
and CD14+ DCs (Figure S3B) were substantially increased in
the tumor compared with paired normal tissues or PB. Previous
studies demonstrated that a subpopulation of Th17-associated
inf-DCs characterized as CD45+ Lin HLA-DR+ CD11c+ CD1c+
CD16 were increased in ovarian and breast tumor ascites
(Segura et al., 2013). We found that both CD1c+ CD16 and
CD1c CD16+ subpopulations were conspicuously increased
in tumor tissues (Figure 3D, left). Morphological analysis showed
that tumor-infiltrating inf-DCs (Figure S3C) displayed typical DC
morphology with numerous dendrites, distinct from the macro-
phage-like morphology of inflammatory macrophages (inf-mac-
rophages; CD45+ Lin HLA-DR+ CD11c+ CD1c CD16+ cells)
(Figure 3D, right). In addition, tumor-infiltrating inf-DCs were
positive for CD80, CD83, CD86, PD1, CD206, HLA-DR, and
CD11c (Figure 3E), suggesting that these cells were immature
DCs. Further study showed that both the frequency and numbers
of inf-DCs were substantially elevated in tumor compared with
those from paired normal tissues and PB or health donors (HD)
(Figure 3F). Inf-macrophages were also substantially increased
in tumor (Figure 3G). However, the percentages and numbers
of inf-macrophages in PB of CRC patients and healthy donorsFigure 2. Characteristics and Distribution of gdT17 Cells in Human CR
(A) Representative flow cytometric analysis of intracellular IL-17, IFN-g, and TNF-
on gdTCR+ cells. One of ten independent experiments is shown. N, normal tissu
(B) Representative flow cytometric analysis of IL-22, IL-10 and IL-4 production by
gdTCR+ cells. One of ten independent experiments is shown. N, normal tissue; T
(C) Single cell suspensions from tumor tissues were stained with a panel of anti
TCRVd2, and anti-human IL-17A) and analyzed by FCM. Left panel shows represe
infiltrating gdT17 cells. Plots were gated on TCRgd+ IL-17A+ cells. One of ten inde
TCRVd1+ cells and TCRVd2+ in tumor-infiltrating gdT17 cells. Data are shown as
(D) Phenotype of tumor-infiltrating gdT17 cells in CRC patients were detected by
independent experiments is shown.
(E) Left panel representative flow cytometric analysis of differentiation-relatedmar
summarized data that show the percentages of Tnaive, Tcm, Tem, and Temra in gd
of IL-17A+ cells in Tnaive, Tcm, Tem, and Temra gd T cells. Plots were gated on
normal tissue; T, tumor.
(F) Bottom left shows that gdT17 cells were detected by FCM. Plots were gated
Bottom right bar diagram shows percentages of IL-17A+ cells in gdT cells and IL-1
normal tissue; TB, tumor border; INT, intratumor. Data are shown as mean ± SE
See also Figure S2.were no different (Figure 3G). These data suggest that tumor-
infiltrating inf-DCs and inf-macrophages are primary inflamma-
tory myeloid cell subsets in human CRC.
Our previous study demonstrated that gdT17 cells were acti-
vated by IL-23 in skin inflammation (Cai et al., 2011). We found
that IL-23 was substantially increased both at the transcriptional
and protein level in tumor-infiltrating inf-DCs (Figure S3D). Then
we examined whether microbial products stimulated inf-DCs to
produce IL-23. Heat-killed E. coli, Pam3, LPS, and CD40L acti-
vated inf-DCs but not inf-macrophages to produce IL-23 (Fig-
ure 3H). To determine the role of IL-23 in gdT17 cell polarization
in human CRC, we stimulated gdT cells from normal tissues with
IL-23 or supernatants from tumor or paired normal tissues. IL-17
production by gdT cells could be induced by supernatants
derived from tumors (TS) or IL-23, but not by supernatants
from paired normal tissues (NS) (Figure 3I, left). Furthermore,
TS-induced IL-17 production by gdT cells could be blocked
by IL-23p19 neutralizing antibody (Figure 3I, left; Figure S3E).
To further decode whether inf-DCs activated by microbial
products could polarize gdT17 cells, we cocultured both pre-
activated and resting tumor-infiltrating inf-DCs with gdT cells
isolated from normal tissues. We found that both resting and
activated inf-DCs could effectively induce gdT17 cells in an
IL-23-dependent manner (Figure 3I, right). However, inf-DCs
activated by microbial products were more efficient at eliciting
gdT17 cell polarization than resting inf-DCs. In addition, TS and
activated inf-DCs could promote gdT17 cell proliferation and
survival in vitro (Figures S4A–S4D). Collectively, these findings
suggest that tumor-infiltrating inf-DCs activated by microbial
products induce gdT17 polarization.
Epithelial Barrier Failure and Bacterial Product Release
in Human CRC
Having demonstrated that the primary commensal bacteria
E. coli products stimulate inf-DCs to produce IL-23, we hypo-
thesized that epithelial barrier failure caused by tumor develop-
ment might result in commensal bacterial product release in
CRC, which in turn could stimulate inf-DCs for gdT17 cell polar-
ization. Indeed, epithelium structure in the tumor was deterio-
rated as revealed by H&E staining (Figure 4A). We further stained
the tumor tissues with tight junction proteins such as ZO-1,C
a production by gdT cells in tumor and paired normal tissues. Plots were gated
e; T, tumor.
gdT cells in tumor and paired normal tissues. Plots were gated on CD45+ CD3+
, tumor.
bodies (anti-human CD45, anti-human CD3, anti-human TCRVd1, anti-human
ntative flow cytometric analysis of TCRVd1+ cells and TCRVd2+ cells in tumor-
pendent experiments is shown. Right panel bar diagram shows percentages of
mean ± SEM; n = 10; ***p < 0.001.
FCM. Flow plots were gated on CD45+ CD3+ TCRgd+ IL-17A+ cells. One of six
kers of gdT17 cells in the tumor and paired normal tissues. Up right panel shows
T cells. Bottom right panel shows summarized data that show the percentages
CD45+ CD3+ TCRgd+ cells. One of six independent experiments is shown. N,
on CD45+ CD3+ TCRgd+ cells. One of ten independent experiments is shown.
7A+ gdT cells in CD3+ cells in normal, tumor border, and intratumor tissues. N,
M; n = 10; **p < 0.01; ***p < 0.001.
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Innate gdT17 Cells in Human CRCclaudin-2, and pancytokeratin to detect the epithelial barrier
integrity. Both ZO-1 and claudin-2 were markedly decreased
and disordered in the tumor tissues compared with adjacent
normal tissues (Figure 4B). In addition, the mRNA expression
levels of transcripts encoding ZO-1, OCLN, and MUC2 were
substantially decreased in the tumors compared to those in the
paired normal tissues (Figure 4C). To investigate the bacterial
product invasion in CRC, we rigorously washed fresh tumor
and paired normal tissues and homogenized them for tissue
LPS detection. LPS level was substantially increased in tumor
(Figure 4D). To investigate whether commensal bacteria invaded
into the tumor, we detected paraffin sections by bacterial uni-
versal 16sRNA by using in situ hybridization. We observed that
bacterial 16sRNA was located in the tumor border and adjacent
normal tissues (Figure 4E). Bacterial universal 16sRNA was
substantially increased in tumor tissues (Figure 4F), suggesting
that bacterial invasion occurred in the tumor. Similar results
were observed with bacterial universal 16sRNA quantitative
PCR analysis in the tumor and paired normal tissues (Figure 4G).
These data suggest that tumor-elicited epithelial barrier failure
might lead to commensal bacteria and bacterial product inva-
sion, which correlates with inf-DC activation and IL-23 secretion
in human CRC.
gdT17 Cell-Derived Cytokines Promote the
Recruitment, Proliferation, and Survival of PMN-MDSC
We next examined how gdT17 cells played a role in tumor-
elicited inflammation and immune suppression in human CRC.
We noted that gdT cells isolated from normal tissues could be
induced to produce IL-8, TNF-a, and GM-CSF in addition to
IL-17 (Figure 5A). IL-17A, IL-8, and GM-CSF production by gdT
cells was partly dependent on IL-23, whereas TNF-a production
was independent (Figure 5A). To further dissect whether IL-8,Figure 3. gdT17 Cells Are Activated by Inf-DCs via IL-23
(A) Left panel shows that the relative mRNA level of IL-23p19 in tumor and paire
GAPDH. Right panel shows concentrations of IL-23 in tumor and paired normal tis
Data are shown as mean ± SEM; n = 5; **p < 0.01.
(B) Left panel shows representative images of paraffin sections from CRC patient
or anti-human CD68 (lower, red) by IF staining (scale bars represent 100 mM). Ri
(scale bars represent 100 mM). The arrows indicate colocalizations of CD11c and
independent experiments is shown. N, normal tissue; TB, tumor border; INT, intr
(C) Percentages (in CD45+ Lin cells) and absolute numbers (in 1 3 106 CD45
autologous PB were quantified by FCM. N, normal tissue; T, tumor; PB, periphe
(D) Left panel shows representative flow cytometric analysis of inf-DCs (CD45+ L
and paired normal tissues from CRC patients. Plots were gated on CD45+ Lin ce
May-Grunwald staining that showsmorphology of tumor-infiltrating inf-DCs and in
cell sorting (FACS). One of six independent experiments is shown. N, normal tiss
(E) Phenotypes of tumor-infiltrating inf-DCs (CD45+ Lin CD11c+ HLA-DR+ CD1c
were detected by FCM. One of three independent experiments is shown.
(F) Percentages and absolute numbers (in 13 106 CD45+ Lin cells) of inf-DCs in
quantified by FCM. N, normal tissue; T, tumor; PB, peripheral blood; HD, healthy
(G) Percentages and absolute numbers (in 13 106 CD45+ Lin cells) of inf-macro
normal tissue; T, tumor; PB, peripheral blood; HD, healthy donors. Data are show
(H) Sorted tumor-infiltrating inf-DCs (left) and inf-macrophages (right) were treat
Medium alone) for three days in vitro. IL-23 levels in the supernatants were dete
(I) Left panel shows that gdT cells sorted from normal tissues were treated with h
control mAb respectively for 14 days. Right panel shows that the sorted gdT cells w
killed E. coli for three days) sorted from paired tumor tissues in the medium con
IL-17A+ cells in gdT cells were determined by FCM. NS, normal tissue-derived su
n = 6; *p < 0.05; **p < 0.01.
See also Figures S3 and S4.TNF-a, and GM-CSF were produced by gdT17 cells in the tumor
tissues, we detected intracellular cytokines of tumor-infiltrating
gdT17 cells by FCM. As shown in Figure 5B, more than 50% of
tumor-infiltrating gdT17 cells also produced IL-8, TNF-a, and
GM-CSF. IL-8+ gdT17 cells, TNF-a+ gdT17 cells and GM-CSF+
gdT17 cells were substantially increased in tumor compared
with those in paired normal tissues (Figure 5C). In contrast, the
production of IL-8, TNF-a, and GM-CSF in Th17 cells was
marginally increased in tumor tissues (Figures S5A and S5B)
but much lower than that in gdT17 cells. Moreover, CD161+
CCR6+ gdT17 cells isolated from tumor tissues produced
much more IL-8, TNF-a, and GM-CSF than those cells from
paired normal tissues (Figure 5D).
Recent studies have shown that TNF-a (Sade-Feldman et al.,
2013; Zhao et al., 2012), IL-17A (He et al., 2010), and GM-CSF
(Kapanadze et al., 2013) are involved in the accumulation of
tumor-infiltrating MDSCs in mice. MDSCs are one of the major
immunosuppressive cell subsets in the tumor microenvironment
(Gabrilovich et al., 2012). To investigate the impact of gdT17 cells
and secreted cytokines on MDSCs in human CRC, we detected
MDSCs in tumor and paired fresh normal tissues by FCM. We
found that PMN-MDSCs characterized as CD45+ Lin HLA-
DR CD11b+ CD33+ CD66b+ (Figures S6A–S6D) were predomi-
nant and greatly increased in tumors compared to those in
paired normal tissues (Figure 6A, upper). In contrast, M-MDSCs
were scarce in tumor tissues (Figure 6A, lower; Figure S6D). The
detailed gating strategy was shown in Figures S6A–S6C. Sorted
tumor-infiltrating PMN-MDSCs displayed typical polymorpho-
nuclear granulocyte morphology (Figure 6B). These PMN-
MDSCs produced much more arginase-I (Figure 6C) and ROS
(Figure 6D) compared with autologous PMNs. Furthermore,
PMN-MDSCs isolated from tumor potently inhibited the prolifer-
ation of activated autologous T cell (Figures 6E and 6F) and IFN-gd normal tissues was determined by quantitative RT-PCR and normalized to
sue-derived supernatants were detected by ELISA. N, normal tissue; T, tumor.
s stained with anti-human IL-23p19 (green) and anti-human CD11c (upper, red)
ght panel represents magnified view indicated by the red box in the left panel
IL-23p19 intumor (upper), but not for CD68 and IL-23p19 (lower). One of three
atumor.
+ Lin cells) of CD11c+ HLA-DR+ cells in normal tissues, paired tumor, and
ral blood. Data are shown as mean ± SEM; n = 20; **p < 0.01.
in CD1c+ CD16) and inf-macrophages (CD45+ Lin CD1c CD16+) in tumor
lls. One of ten independent experiments is shown. Right panel shows Giemsa/
f-macrophages (scale bars represent 20 mM) sorted by fluorescence-activated
ue; T, tumor.
+ CD16) and inf-macrophages (CD45+ Lin CD11c+ HLA-DR+ CD1c CD16+)
tumor, paired normal tissues, autologous PB and PB from healthy donors were
donors. Data are shown as mean ± SEM; n = 20; **p < 0.01.
phages in the same set of samples as in above (F) were quantified by FCM. N,
n as mean ± SEM; n = 20; NS, no statistical significance; *p < 0.05; **p < 0.01.
ed with various ligands (heat-killed E. coli, Pam3, LPS, CD40L, E.coli DNA or
cted by ELISA. Data are shown as mean ± SEM; n = 6; *p < 0.05; **p < 0.01.
eat-killed E.coli, NS, TS, IL-23, TS with IL-23 neutralizing antibody or TS with
ere coculturedwith resting inf-DCs or pre-activated inf-DCs (treated with heat-
taining IL-23 neutralizing antibody or not for 2 weeks in vitro. Percentages of
pernatants; TS, tumor-derived supernatants. Data are shown as mean ± SEM;
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Innate gdT17 Cells in Human CRCproduction (Figure 6G). However, PMN from healthy donors did
not show any suppressive activity (Figures S6E and S6F). We
also compared the frequencies and numbers of M-MDSCs and
PMN-MDSCs in tumor with paired normal tissues and PB, as
well as health donor PB. We found that the frequency of both
M-MDSCs (Figure 6H, left) and PMN-MDSCs (Figure 6I, left)
was substantially increased in tumor compared with paired
normal tissues, but regarding the absolute number, only PMN-
MDSCs were greatly increased. Besides, PMN-MDSCs were
abundant and about 80-fold more than M-MDSCs in tumor
tissues (Figure 6J).
We next examined whether the accumulation of PMN-MDSCs
was the result of gdT17 cell activation. To this end, we used an
in vitro coculture transwell system to assess the contribution of
gdT17 cells in tumor-infiltrating PMN-MDSCmigration, prolifera-
tion, and survival. We found that activated gdT17 cells isolated
from tumor tissues could effectively promote tumor-infiltrating
PMN-MDSC migration within 6 hr in IL-8 and GM-CSF-depen-
dent manner (Figure 6K). In addition, tumor-infiltrating PMN-
MDSCs were substantially expanded within 24 hr when they
were cocultured with paired gdT17 cells (Figure 6L). The
enhanced PMN-MDSC proliferation mediated by gdT17 cells
could be blocked by IL-17A and GM-CSF neutralizing anti-
bodies. More strikingly, gdT17 cells substantially promoted
PMN-MDSC survival, and this effect was substantially blocked
by IL-8, IL-17A, and TNF-a neutralizing antibodies (Figure 6M).
In contrast, gdT17 cells from normal tissues showed less activity
to stimulate PMN-MDSC migration, proliferation, and survival
(Figures S6G–S6I). Collectively, these data show that gdT17
cells, via IL-17A, IL-8, GM-CSF, and TNF-a, promote the accu-
mulation and expansion of PMN-MDSC to facilitate immunosup-
pression in vitro.
gdT17 Cells Impact Advanced Clinicopathological
Features in Human CRC
To investigate the implication of gdT17 cells to clinical features of
human CRC, we collected and analyzed clinical data from 117
CRC patients (Table S1). We found that the frequency of
tumor-infiltrating gdT17 cells was substantially and positively
correlated with advancing TNM stages (Figure 7A). Similar
results were observed when the absolute numbers of gdT17 cellsFigure 4. Epithelial Barrier Failure and Bacterial Products invasion in H
(A) Left panel shows representative histological images of the tumor and adjacent
represent magnified view indicated by the green box of the normal area (middle) an
middle panel indicates the integrated epithelium structure in the normal tissue. A
tumor. NT, normal tissue; TB, tumor border; INT, intratumor.
(B) Left panel shows representative images of ZO-1 (upper, green) and claudin-2
tumor and normal tissues (scale bars represent 100 mM). Middle and right panels r
the red box of tumor area (right) in the left panel, respectively. One of three in
intratumor.
(C) The relative mRNA levels ofMUC2,CLDN2, ZO-1, andOCLN in the tumor and
to GAPDH. N, normal tissue; T, tumor. Data are shown as mean ± SEM; n = 5; N
(D) ELISA assay to measure LPS concentrations in supernatants from tumor and p
tissue samples used. N, normal tissue; TB, tumor. Data are shown as mean ± SE
(E) Representative image of bacterial 16 RNA invaded into tumor by fluorescence
The arrows indicate the location of 16 RNA (red) in tumor border. N, normal tiss
shown.
(F) The 16 RNA+ bacteria in tumor and paired normal tissues were counted by FIS
**p < 0.01.
(G) The 16 RNA+ bacteria in the tumor and paired normal tissues were detectedin one million CD45+ cells were analyzed (Figure 7B). In contrast,
the frequency of Th17 or Tc17 cells did not show overall correla-
tionwith TNMstages, although Th17 cells did increase in stage III
human CRC (Figures S7A and S7B). The percentages of tumor-
infiltrating gdT17 cells were also positively associated with other
clinicopathological features, including tumor size, tumor inva-
sion, lymphatic and vascular invasion, lymph node metastasis,
and serum CEA levels (Figure 7C). Another cohort of patients
was also examined for a correlation between gdT17 cells and
inf-DCs, PMN-MDSCs, and IL-23 and IL-17 levels in the tumor.
We found that the percentages of tumor-infiltrating gdT17
cells were positively associated with tumor-infiltrating inf-DCs,
PMN-MDSCs, and IL-23 and IL-17 levels in tumor tissues
(Figure 7D). In addition, IL-23 expression was also correlated
with inf-DCs accumulation and total IL-17 protein expression
(Figure S7C). These findings suggest that tumor-infiltrating
gdT17 cells are associated with tumor invasiveness and progres-
sion. Thus the frequency and numbers of tumor-infiltrating gdT17
cells might be a prognostic factor in human CRC.
DISCUSSION
In this study, we clearly demonstrate that innate gdT cells are
the major source of IL-17 in human CRC. gdT17 cell activation
is triggered by IL-23, which is highly expressed in human CRC
tissues. The source of IL-23 is mainly from tumor-infiltrating
inf-DCs, which is activated by microbial pathogen invasion as
a consequence of tumorous epithelial barrier deterioration.
These gdT17 cells not only secrete large amounts of IL-17 but
also other cytokines including IL-8, GM-CSF, and TNF-a. More
importantly, our in vitro studies demonstrate that tumor-
infiltrating gdT17 cells chemoattract PMN-MDSCs and further
expand and provide survival advantage for them to maintain
immune suppressive activity via secretion of these cytokines.
We also demonstrate a strong and positive correlation between
tumor-infiltrating gdT17 cells and advanced clinicopathological
features including TNM stages, tumor sizes, and lymphatic and
vascular invasions, all of which are signatures of poor clinical
outcome. Taken together, these findings suggest that innate
gdT17 cells contribute to human CRC development and
progression.uman CRC
tissues by H&E staining (scale bars represent 100 mM). Middle and right panels
d the red box of the tumor area (right) in the left panel, respectively. Arrow in the
rrows in the right panel indicates the deteriorated epithelium structure in the
(lower, green) expressions by IF staining in paraffin sections containing both
epresent magnified view indicated by the green box of normal area (middle) and
dependent experiments is shown. N, normal tissue; TB, tumor border; INT,
paired normal tissues were determined by quantitative RT-PCR and normalized
S, no statistical significance; *p < 0.05; **p < 0.01.
aired normal tissues. The LPS levels were normalized back to the weight of the
M; n = 10; **p < 0.01.
in situ hybridization (FISH) in paraffin sections (scale bars represent 100 mM).
ue; TB, tumor border; INT, intratumor. One of ten independent experiments is
H. N, normal tissue; T, tumor border. Data are shown as mean ± SEM; n = 10;
by RT-PCR; data are analyzed by Fisher’s exact test; n = 10.
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Figure 5. Inf-DCs Activated by Bacterial Products Stimulate gdT Cells Producing IL-17A, IL-8, TNF-a, and GM-CSF
(A) gdT cells sorted from normal tissues were cocultured with resting or preactivated inf-DCs (pretreated with heat-killed E. coli for 3 days) in medium containing
IL-23 neutralizing antibody or not for 3 days in transwell system. Then, gdT cells were harvested and incubated in serum-free medium for another 3 days.
Concentrations of IL-17A, IL-8, TNF-a, and GM-CSF in the gdT cells supernatants were determined by ELISA. Data are shown as mean ± SEM; n = 6; NS, no
statistical significance; *p < 0.05; **p < 0.01.
(B) Representative flow cytometric analysis of intracellular IL-8, GM-CSF, TNF-a, and IL-17A production by gdT cells in tumor and paired normal tissues. Plots
were gated on TCRgd+ cells. One of six independent experiments is shown. N, normal tissue; T, tumor.
(legend continued on next page)
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Innate gdT17 Cells in Human CRCgdT17 cells play a critical role in the pathogenesis of several
inflammation-associated diseases in mice (Cai et al., 2011;
Gray et al., 2013; Pantelyushin et al., 2012; Park et al., 2010;
Petermann et al., 2010; Shichita et al., 2009; Sutton et al.,
2009). The role of gdT17 cells and their characteristics in human
inflammation-associated diseases are emerging (Caccamo
et al., 2011; Fenoglio et al., 2009; Kenna et al., 2012). In murine
colon cancer models, abT cells are considered to be the major
IL-17 producer (Grivennikov et al., 2012; Wu et al., 2009). How-
ever, it was unclear whether IL-17 is also mainly produced by
Th17 cells in human CRC. Despite two recent studies showing
that both IL-17 transcription and protein expression are substan-
tially increased in human CRC tissues (Chung et al., 2013; Toso-
lini et al., 2011), it was assumed that Th17 cells were the source
of IL-17, but this was not directly proved. We have used flow
cytometric analysis and have demonstrated that IL-17 is almost
exclusively secreted by CD3+ cells including Th17, Tc17, and
gdT17 cells, but not ILCs. In addition, gdT17 cells are the major
IL-17 producer both in percentages and absolute numbers.
This conclusion is also supported by ELISA data. Thus, our study
formally establishes gdT17 cells as the major IL-17-producing
cells in human CRC.
The murine gdT17 cells share many characteristics with other
IL-17-producing cell subsets (Hedrick et al., 2009), including
constitutive expression of CCR6 and CD161. A recent study
has shown that human PB IL-17+ Vg9Vd2 T cells have a predom-
inant terminally differentiated phenotype (CD45RA+ CD27) and
express granzyme B, TRAIL, FasL, and CD161 (Caccamo et al.,
2011). In our study, human tumor-infiltrating gdT17 cells have a
predominant effector memory phenotype (CD45RA CD27)
and express CCR6 and CD161, but not granzyme B, perforin,
FasL, TRAIL, NKG2D, NKp30, NKp44, NKp46, CD25, or
CD122. In contrary to the PB IL-17+ Vg9Vd2 T cells, the dominant
tumor-infiltrating gdT17 cells are Vd1+ cells. Moreover, tumor-
infiltrating gdT17 cells produce both IL-17 and TNF-a, but not
IFN-g in tumor tissues. These data suggest that human tumor-
infiltrating gdT17 cells are a subset of multifunctional IL-17-pro-
ducing cells with an effector memory phenotype and limited
cytotoxicity.
IL-23 secreted bymyeloid cells is considered to be a promoter
in the progression of CRC in mice and humans (Langowski et al.,
2006). Our previous study showed that myeloid cells secreted
IL-23 to promote inflammation in mouse psoriasis model (Cai
et al., 2011). Here, we find that IL-23 is substantially increased
in human CRC tumor tissues, consistent with previous studies
(Langowski et al., 2006). Previous studies in CPC-APC mouse
colon cancer model have shown that IL-23 is primarily secreted
by macrophages (Grivennikov et al., 2012). On the contrary,
studies in human showed that both DCs andmacrophages could
produce IL-23 (Cai et al., 2011; Langowski et al., 2006), high-
lighting the differences between humans and mice. We find
that tumor-infiltrating inf-DCs are the major source of IL-23.
Upon bacterial product stimulation, tumor-infiltrating inf-DCs,
but not inf-macrophages, produce IL-23. Deregulation of tight(C) Percentages of IL-17A+ IL-8+ gdT cells, IL-17A+ GM-CSF+ gdT cells, and IL-1
mean ± SEM; n = 6;*p < 0.05; **p < 0.01.
(D) IL-8, GM-CSF, and TNF-a in the sorted CD161+ CCR6+ gdT cells supernatan
See also Figure S5.junctions and cell-cell contacts has been previously described
in advanced human adenocarcinoma (Wang et al., 2011). In
addition, gut microbiota has been suggested to contribute to
inflammation-associated cancer and to the regulation of the
host immune system (Hooper et al., 2012). In our study, bacterial
16sRNA is detected in situ in tumor and tumorous LPS amounts
are also substantially increased compared with normal tissues.
Moreover, consistent with previous studies (Grivennikov et al.,
2012), tumorous epithelial barrier failure in human CRC is
demonstrated by histology analysis and the decrease and dis-
order of tight junction proteins. These data suggest that inf-DC
accumulation and activation in human CRC might be a result
of microbial product invasion caused by barrier deterioration,
which in turn links to tumor-elicited inflammation via gdT17 cell
activation.
gdT17 cells are multifunctional inflammatory cells that can
produce various cytokines (Cai et al., 2011; Pantelyushin et al.,
2012). Tumor-infiltrating gdT17 cells in human CRC not only
produce large amounts of IL-17 but also secrete IL-8, TNF-a,
and GM-CSF. Moreover, the production of IL-8 and GM-CSF
in gdT17 cells is partly inf-DC- and IL-23-dependent. In contrast,
Th17 cells secrete marginal amounts of these cytokines. Previ-
ous studies have shown that TNF-a (Sade-Feldman et al.,
2013; Zhao et al., 2012), IL-17 (He et al., 2010), and GM-CSF
(Kapanadze et al., 2013) are involved in the mobilization and
recruitment of tumor-infiltrating MDSCs in mice. Indeed, we
find that PMN-MDSCs, but not M-MDSCs, are preferentially
accumulated in the tumor microenvironment and positively
correlate with tumor-infiltrating gdT17 cells in human CRC.
Further in vitro studies have demonstrated that tumor-infiltrating
gdT17 cells also promote PMN-MDSC proliferation and survival
via IL-17A, IL-8, TNF-a, and GM-CSF. Our findings are consis-
tent with previous preclinical studies demonstrating that IL-17
recruits Gr-1+ CD11b+ MDSCs to promote tumor growth (He
et al., 2010). In addition, our findings suggest that gdT17 cells
promote recruited MDSCs for enhanced survival and further
expansion. Although it is difficult to determine whether these
PMN-MDSCs are from PB neutrophils, PMN-MDSCs in human
CRC have elevated arginase-I and ROS production, and potent
immune suppression of T cell proliferation and function. Taken
together, we speculate that gdT17 cells might convert tumor-
elicited inflammation to an immunosuppressive environment
by promoting PMN-MDSC accumulation and expansion in the
tumor area. Subsequently, these events govern human CRC
development and progression.
In summary, our study has revealed innate gdT17 cells to be
key regulators in human CRC-elicited inflammation and immu-
nosuppression. This appears to be initiated through tumorous
epithelial barrier disruption leading to microbial product release
that correlates with inf-DC accumulation and activation, thus
promoting gdT17 cell polarization. Activated gdT17 cells secrete
large amounts of cytokines including IL-17, TNF-a, IL-8, and
GM-CSF, which might mobilize and recruit PMN-MDSCs
to establish a potent immunosuppressive environment for7A+ TNF-a+ gdT cells in gdT cells were quantified by FCM. Data are shown as
ts were detected by ELISA. Data are shown as mean ± SEM; n = 6; **p < 0.01.
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Innate gdT17 Cells in Human CRCpromoting tumor progression and immune evasion. It is worth
noting that these in vitro studies are correlative and descriptive
due to the nature of human subject studies. Nevertheless, our
findings suggest that gdT17 cells might be a prognostic factor
of human CRC, and eradication of these cells might have a
potential for effective treatment.
EXPERIMENTAL PROCEDURES
Clinical Specimens
Colorectal tumor (T, homogeneous cellularity, without foci of necrosis), paired
normal intestine tissues (N), and some fresh PB were obtained from 154
patients with colorectal adenocarcinoma who underwent surgical resection
at the Second Affiliated Hospital, Zhejiang University School of Medicine. To
study the distribution of gdT17 cells, we collected intratumoral (INT) tissues
or tissues from tumor border (TB) and paired normal tissues from the same
patients. Autologous PB was collected before surgery. Normal autologous
tissue was obtained from a macroscopically normal part of the excised intes-
tine, at least 5 cm away from the tumor. None of the patients had received
radiotherapy or chemotherapy before operation. Control PB samples were
obtained from 28 healthy donors from the Zhejiang Blood Center, all of
whom were negative for antibodies against hepatitis C virus, hepatitis B virus,
HIV, and syphilis. All samples were anonymously coded in accordance with
local ethical guidelines (as stipulated by the Declaration of Helsinki), and
written informed consent was obtained and the protocol was approved by
the Review Board of the Second Affiliated Hospital of Zhejiang University
School of Medicine.
Cell Isolation and Culture
Freshly excised tissues were cut into small pieces and then digested in RPMI
1640 medium containing 2% FBS, type IV collagenase (1 mg/ml), and hyal-
uronidase (10 ng/ml) for 2–3 hr at 37C. Inf-DCs, inf-macrophages, total gdT
cells, CD161+ CCR6+ gdT17 cells, CD161+ CCR6+ Th17 cells, CD161+
CCR6+ Tc17 cells, Th17 cells, Tc17 cells, and PMN-MDSCs in single cell
suspensions were incubated with various antibody cocktails (Table S2) and
then sorted by Aria II cell sorter (BD Biosciences). PB lymphocytes were
isolated after centrifugation on a Ficoll gradient followed by cell sorting. The
purity of all sorted cells was greater than 90%.Figure 6. gdT17 Cells Promote the Migration, Proliferation, and Surviv
(A) Representative flow cytometric analysis of M-MDSC (upper) and PMN-MDSC
on CD45+ Lin HLA-DR CD33+ cells. One of six independent experiments is sh
(B) Giemsa/May-Grunwald staining shows morphology of tumor-infiltrating PM
independent experiments is shown.
(C) PMN-MDSC cells sorted from tumor tissues and paired PMN from PB of sa
supernatants were detected by ELISA. Data are shown as mean ± SEM; n = 6; *
(D) Similar to (C), ROS levels in PMN-MDSC or PMN were measured by staining w
of three independent experiments is shown.
(E and F) Sorted PMN-MDSC were cocultured with CFSE-pre-labeled CD3+ T ce
4:1; 2:1; 1:1; 0.5:1 and 0:1) in the presence of anti-CD3 and anti-CD28 mAbs. CD
experiments is shown (E). Bar diagram summarizes the percentages of prolifera
**p < 0.01.
(G) PMN-MDSC from tumor tissues were cocultured with CD3+ T cells from autolo
by ELISA. Data are shown as mean ± SEM; n = 6; *p < 0.05; **p < 0.01.
(H and I) Percentages and absolute numbers (in 13 106 CD45+ Lin HLA-DR CD
tissues (n = 6), PB (H): n = 3; (I): n = 5) from CRC patients and PB (H): n = 3; (I): n = 5
PB, autologous peripheral blood; HD, healthy donors. Data are shown as mean
(J) Absolute numbers (in 13 106 CD45+ LinHLA-DRCD33 cells) of M-MDSCs
SEM; n = 7; ***p < 0.001.
(K, L, and M) Sorted tumor-infiltrating PMN-MDSCs (upper well) and CD161+ CC
transwell plate for 6 hr, 24 hr, or 72 hr respectively. For migration assay (K), cells i
tumor-infiltrating PMN-MDSCswere prelabeled with CFSE, the proliferation of PM
was added in the cocultured medium for the last 15 min, PI+ PMN-MDSC cells w
0.01. Similar results were obtained by coculture in vitro polarized gdT17 cells wit
See also Figure S6.Flow Cytometry
For extracellular staining of immune markers, we prepared single cell suspen-
sions by mechanic dispersion and enzymatic digestion of normal and tumor
tissues. We preincubated fresh tissue cells (1 3 106/ml) in a mixture of PBS,
2% fetal calf serum, and 0.1% (w/v) sodium azide with FcgIII/IIR-specific
antibody to block nonspecific binding and stained with different combinations
of fluorochrome-coupled antibodies (Table S2). The antibody cocktails for inf-
DCs, inf-macrophages, and M-MDSCs lineage assay were CD3, CD15, CD19,
CD20, CD56, CD235a, or CD3, CD19, CD20, CD56, CD235a; for PMN-MDSCs
assay was CD3, CD14, CD16, CD19, CD20, CD56, CD235a, or CD3, CD19,
CD20, CD56, CD235a. For intracellular staining, we followed the manufac-
turer’s protocol after 6 hr incubation in the presence of Leukocyte Activation
Cocktail (BD PharMingen). Fluorescence data were collected on a FACSCanto
II system (BD Biosciences) and analyzed with FlowJo software (Tree Star).RNA Extraction and Gene Expression by qPCR
Tissue and cell RNAs were extracted with the RNeasy Micro Kit (QIAGEN)
and reverse transcribed into cDNA by oligo-dT primer (Invitrogen) and
Superscript First Strand Synthesis System (Invitrogen). cDNA was analyzed
by real-time PCRwith SYBRGreen I Master Mix (Roche) with the StepOnePlus
instrument (Applied Biosystems) for the target genes (Table S3). Data were
presented as arbitrary units and calculated as 2(Ct(GAPDH–gene of interest)).In Vitro gdT17 Cell Polarization
gdT cells isolated from normal tissues were cultured in the conditional
medium containing heat-killed E. coli, supernatants derived from normal
tissues (NS), supernatants derived from tumor tissues (TS), or recombinant
human IL-23 (10 mg/ml, R&D Systems). IL-23 neutralizing antibody (Clone
24901, 0.1mg/ml,) was added when needed. At day 14, IL-17+ cells were
detected by FCM.ELISA Assay and LPS Detection
IL-23, IL-17A, IL-8, TNF-a, GM-CSF, and IFN-g were measured by ELISA kits
(R&D Systems). Arginase I levels were also determined by an ELISA kit
(BioVendor). Tissue LPS levels were analyzed in duplicate wells in 96-well
plates according to the manufacturer’s instructions with Limulus Amoebocyte
Lysate (LAL) assay QCL-1000 (Lonza, ValaisSwitzerland). The LPS levels were
normalized back to the weight of the tissue samples used.al of PMN-MDSCs
(lower) in tumor and paired normal tissues from CRC patients. Plots were gated
own.
N-MDSC cells sorted by FACS (scale bars represent 15 mm). One of three
me patient were cultured in vitro for 6 hr. Concentrations of arginase I in the
p < 0.05.
ith 5,6-chloromethyl-20,70-dichlorodihydrofluorescein diacetate (DCFDA). One
lls isolated from autologous PB at different ratios (PMN-MDSC/CD3+ T cells in
3+ T cell proliferation was evaluated on day 6 by FCM. One of five independent
ted cells (CFSElo) in CD3+ T cells (F). Data are shown as mean ± SEM; n = 5;
gous PB for 12 hr. Concentrations of IFN-g in the supernatants were detected
33 cells) of M-MDSCs (H) and PMN-MDSCs (I) in tumor (n = 6), normal paired
) from healthy donors (HD) were quantified by FCM. N, normal tissue; T, tumor;
± SEM; NS, no statistical significance; *p < 0.05; **p < 0.01; ***p < 0.001.
and PMN-MDSCs in the same sets of tumor tissues. Data are shown asmean ±
R6+ gdT cells or in vitro polarized gdT17 cells (lower well) were cocultured in
n the lower well were collected and counted. For proliferation assay (L), sorted
N-MDSCswas detected by FCMafter 24 hr coculture. For survival assay (M), PI
ere examined by FCM. Data are shown as mean ± SEM; n = 6; *p < 0.05; **p <
h tumor-infiltrating PMN-MDSCs in the same condition as above.
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For PMN-MDSCs or PMN-mediated T cell suppression experiments, sorted
tumor-infiltrating PMN-MDSCs or PMN from health donors were cocultured
with autologous CFSE labeled T cell (2 3 104) at 4:1, 2:1, 1:1, and 0:1 in the
medium containing CD3 (10 mg/ml, R&D Systems) and CD28 (10 mg/ml, R&D
Systems). At day 6, cells were harvested, and CFSE CD3+ T cells were
detected by FCM.
Immunofluorescent Staining and Morphological Analysis
Paraffin-embedded and formalin-fixed samples were cut into 5 mM sections,
which were then processed for IF staining or H&E staining. Immunofluores-
cence was performed with antibodies to pan-TCRgd, IL-17A, IL-23p19,
CD11c, CD68, ZO-1, Claudin-2, and pan-Cytokeratin. Secondary antibodies
were Alexa Fluor 488- or 647-conjugated goat anti–mouse IgG or Dylight
488- or 649-conjugated goat anti-rabbit IgG (Invitrogen). Images were
acquired with a confocal microscopy (Zeiss LSM 710, Carl Zeiss). For mor-
phological analysis, sorted inf-DCs, inf-macrophages, or PMN-MDSCs were
subjected to cytospin and stained with May-Grunwald/Giemsa. Pictures
were taken with a CFW-1308C color digital camera (Scion Corporation) on a
Leica DM 4000 B microscope.
Statistical Analysis
Results were expressed as means ± SEM. Statistical analysis was performed
with GraphPad Prism software version 6.1. The statistical significance of
differences between groups was determined by the Student’s t test. Correla-
tions between parameters were assessed with the Pearson correlation anal-
ysis and linear regression analysis, as appropriate. All data were analyzed
with two-tailed tests unless otherwise specified, and a p value < 0.05 was
considered statistically significant.
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